Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Point-of-Care Diagnostics & Biosensors Europe 2018

Jane Brock's Biography



Jane Brock, Assistant Professor, Harvard Medical School; Medical Director Surgical Pathology Grossing Room and Associate Pathologist, Brigham & Women's Hospital

Jane Brock is an Assistant Professor of Pathology at Harvard Medical School and Associate Pathologist at Brigham and Women's Hospital (BWH) and Dana Farber Cancer Institute (DFCI), Boston. She covers both general surgical pathology and a high volume subspecialty breast pathology service including institutional consults for DFCI. She evaluates pathology for breast cancer clinical trials running at the DFCI and has focused her academic research on pathologic prognostic factors in breast cancer. She is the Medical Director of the BWH Surgical Pathology Grossing Room, currently Acting Chief of the Breast Pathology Division, and supervises the training of residents and fellows in surgical pathology and breast pathology at BWH regularly teaching medical students, residents and fellows in breast pathology diagnosis. She has given national and international talks and educational workshops to physicians and non-physicians on the subjects of breast cancer pathology, biopsy handling, and point of care needs in breast cancer diagnostics.

Jane Brock Image

Rapid Diagnosis of Breast Cancer - iInnovative Approaches with a Focus on Low and Middle-Income Countries

Wednesday, 6 June 2018 at 11:30

Add to Calendar ▼2018-06-06 11:30:002018-06-06 12:30:00Europe/LondonRapid Diagnosis of Breast Cancer - iInnovative Approaches with a Focus on Low and Middle-Income CountriesPoint-of-Care Diagnostics and Biosensors Europe 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

Breast Cancer care includes prevention, early detection, diagnostics and therapeutics. Therapeutic decisions are made based on traditional prognostic factors including tumor size, lymph node status, and factors obtained from pathological assessment including tumor grade, immunohistochemical profile of Estrogen and Progesterone Receptor (ER and PR) and Her2/neu gene amplification status. Point of care technology is not currently used in this routine pathological assessment, but there are new opportunities to expedite and facilitate diagnosis, primarily driven by the need to provide breast cancer diagnoses in low-resource settings to the tens of thousands of women who develop breast cancer worldwide. This presentation will discuss alternative methods of tissue biopsy handling and imaging and prognostic marker evaluation that can obviate the need for expensive traditional processing equipment and microscopes, and can allow for more rapid cancer diagnosis and biomarker evaluation compared with current traditional methods.


Add to Calendar ▼2018-06-05 00:00:002018-06-06 00:00:00Europe/LondonPoint-of-Care Diagnostics and Biosensors Europe 2018Point-of-Care Diagnostics and Biosensors Europe 2018 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com